<?xml version="1.0" encoding="UTF-8"?>
<p>Regulatory agencies and programs such as the EAC MRH initiative must carry out 2 fundamental tasks: protecting the public against harm and promoting public health. The need for regulatory agencies to perform these functions was dramatically highlighted in the 1960s, when the United States Food and Drug Administration (US FDA) blocked thalidomide’s approval in the US, preventing the severe birth defects that had occurred in many other countries [
 <xref rid="pmed.1003092.ref005" ref-type="bibr">5</xref>]. This incident inspired the Kefauver-Harris Drug Amendments Act in the US and similar legislation in other countries requiring drug manufacturers to prove that medicines are safe and effective before they can be marketed. Today, regulatory agencies across the world also require that drug manufacturers and clinicians report serious adverse events according to strict timelines before and after a medicine’s approval. In addition to analyzing these adverse event reports, regulatory agencies perform a variety of other pharmacovigilance activities to ensure that the medicines available on the market are safe and of high quality [
 <xref rid="pmed.1003092.ref006" ref-type="bibr">6</xref>,
 <xref rid="pmed.1003092.ref007" ref-type="bibr">7</xref>]. Here, we describe some of the best practices that regulatory agencies have identified for carrying out their key functions in hopes that some of these practices may be useful to the EAC MRH initiative as it takes its place on the world stage.
</p>
